185 related articles for article (PubMed ID: 33912168)
61. Hepatitis C viraemia reversibly maintains subset of antigen-specific T-bet+ tissue-like memory B cells.
Chang LY; Li Y; Kaplan DE
J Viral Hepat; 2017 May; 24(5):389-396. PubMed ID: 27925349
[TBL] [Abstract][Full Text] [Related]
62. Direct-Acting Antiviral Therapy for HCV Infection Is Associated With a Reduced Risk of Cardiovascular Disease Events.
Butt AA; Yan P; Shuaib A; Abou-Samra AB; Shaikh OS; Freiberg MS
Gastroenterology; 2019 Mar; 156(4):987-996.e8. PubMed ID: 30445009
[TBL] [Abstract][Full Text] [Related]
63. Persistent gamma delta T-cell dysfunction in chronic HCV infection despite direct-acting antiviral therapy induced cure.
Ghosh A; Mondal RK; Romani S; Bagchi S; Cairo C; Pauza CD; Kottilil S; Poonia B
J Viral Hepat; 2019 Sep; 26(9):1105-1116. PubMed ID: 31074195
[TBL] [Abstract][Full Text] [Related]
64. A prospective study of T- and B-lymphocyte subpopulations, CD81 expression levels on B cells and regulatory CD4(+) CD25(+) CD127(low/-) FoxP3(+) T cells in patients with chronic HCV infection during pegylated interferon-alpha2a plus ribavirin treatment.
Soldevila B; Alonso N; Martínez-Arconada MJ; Morillas RM; Planas R; Sanmartí AM; Martínez-Cáceres EM
J Viral Hepat; 2011 Jun; 18(6):384-92. PubMed ID: 20487258
[TBL] [Abstract][Full Text] [Related]
65. Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients With Chronic Hepatitis C Virus Infection and Cirrhosis.
Maan R; van Tilborg M; Deterding K; Ramji A; van der Meer AJ; Wong F; Fung S; Sherman M; Manns MP; Cornberg M; Hansen BE; Wedemeyer H; Janssen HL; de Knegt RJ; Feld JJ
Clin Gastroenterol Hepatol; 2016 Dec; 14(12):1821-1830.e6. PubMed ID: 27404965
[TBL] [Abstract][Full Text] [Related]
66. Rates of sustained virological response 12 weeks after the scheduled end of direct-acting antiviral (DAA)-based hepatitis C virus (HCV) therapy from the National German HCV registry: does HIV coinfection impair the response to DAA combination therapy?
Bischoff J; Mauss S; Cordes C; Lutz T; Scholten S; Moll A; Jäger H; Cornberg M; Manns MP; Baumgarten A; Rockstroh JK
HIV Med; 2018 Apr; 19(4):299-307. PubMed ID: 29368456
[TBL] [Abstract][Full Text] [Related]
67. Ribavirin Reduces Absolute Lymphocyte Counts in Hepatitis C Virus-Infected Patients Treated With Interferon-Free, Direct-Acting Antiviral Regimens.
Harrington PR; Fleischer R; Connelly SM; Lewis LL; Murray J
Clin Infect Dis; 2015 Sep; 61(6):974-7. PubMed ID: 26021996
[TBL] [Abstract][Full Text] [Related]
68. Patient-derived hepatitis C virus inhibits CD4⁺ but not CD8⁺ T lymphocyte proliferation in primary T cells.
MacParland SA; Chen AY; Corkum CP; Pham TN; Michalak TI
Virol J; 2015 Jun; 12():93. PubMed ID: 26084511
[TBL] [Abstract][Full Text] [Related]
69. High rates of hepatitis C virus (HCV) cure using direct-acting antivirals in HIV/HCV-coinfected patients: a real-world perspective.
Hawkins C; Grant J; Ammerman LR; Palella F; Mclaughlin M; Green R; Mcgregor D; Stosor V
J Antimicrob Chemother; 2016 Sep; 71(9):2642-5. PubMed ID: 27330060
[TBL] [Abstract][Full Text] [Related]
70. Expression of programmed cell death protein 1 and T-cell immunoglobulin- and mucin-domain-containing molecule-3 on peripheral blood CD4+CD8+ double positive T cells in patients with chronic hepatitis C virus infection and in subjects who spontaneously cleared the virus.
Caraballo Cortés K; Osuch S; Perlejewski K; Pawełczyk A; Kaźmierczak J; Janiak M; Jabłońska J; Nazzal K; Stelmaszczyk-Emmel A; Berak H; Bukowska-Ośko I; Paciorek M; Laskus T; Radkowski M
J Viral Hepat; 2019 Aug; 26(8):942-950. PubMed ID: 30972915
[TBL] [Abstract][Full Text] [Related]
71. Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with severe liver fibrosis.
Petta S; Adinolfi LE; Fracanzani AL; Rini F; Caldarella R; Calvaruso V; Cammà C; Ciaccio M; Di Marco V; Grimaudo S; Licata A; Marrone A; Nevola R; Pipitone RM; Pinto A; Rinaldi L; Torres D; Tuttolomondo A; Valenti L; Fargion S; Craxì A
J Hepatol; 2018 Jul; 69(1):18-24. PubMed ID: 29505844
[TBL] [Abstract][Full Text] [Related]
72. Homeostasis of the naive CD4+ T cell compartment during aging.
Kilpatrick RD; Rickabaugh T; Hultin LE; Hultin P; Hausner MA; Detels R; Phair J; Jamieson BD
J Immunol; 2008 Feb; 180(3):1499-507. PubMed ID: 18209045
[TBL] [Abstract][Full Text] [Related]
73. Introduction of direct-acting antiviral agents alters frequencies of anti-GPIIb/IIIa antibody-producing B cells in chronic hepatitis C patients with thrombocytopenia.
Satoh T; Uojima H; Wada N; Takiguchi H; Kaneko M; Nakamura M; Gonda N; Homma M; Hidaka H; Kusano C; Horie R
Platelets; 2023 Dec; 34(1):2161498. PubMed ID: 36597279
[TBL] [Abstract][Full Text] [Related]
74. Elevated CD57 and CD95 expressions are associated with lower numbers of CD4⁺ recent thymic emigrants in HIV-1 infected immune responders following antiretroviral treatment.
Lu I; Eberhard J; Ahmad F; Bhatnagar N; Behrens G; Jacobs R; Schmidt RE; Meyer-Olson D
Immunol Lett; 2014; 158(1-2):1-6. PubMed ID: 24291117
[TBL] [Abstract][Full Text] [Related]
75. Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia.
Alavi M; Law MG; Valerio H; Grebely J; Amin J; Hajarizadeh B; Selvey C; George J; Dore GJ
J Hepatol; 2019 Aug; 71(2):281-288. PubMed ID: 31078544
[TBL] [Abstract][Full Text] [Related]
76. Successful direct-acting antiviral therapy improves circulating mucosal-associated invariant T cells in patients with chronic HCV infection.
Khlaiphuengsin A; Chuaypen N; Sodsai P; Reantragoon R; Han WM; Avihingsanon A; Tangkijvanich P
PLoS One; 2020; 15(12):e0244112. PubMed ID: 33382729
[TBL] [Abstract][Full Text] [Related]
77. [Dynamic changes in programmed death-1 expression on the surface of T cells in chronic hepatitis C patients undergoing interferon therapy].
Dong RQ; Zhou DF; Han R; Zhou JY; Zhao CY; Zhen Z
Zhonghua Gan Zang Bing Za Zhi; 2013 Dec; 21(12):899-902. PubMed ID: 24636290
[TBL] [Abstract][Full Text] [Related]
78. Predictive factors of hepatitis C virus eradication after interferon-free therapy in HIV coinfection.
Domínguez-Domínguez L; Bisbal O; Matarranz M; Lagarde M; Pinar Ó; Hernando A; Lumbreras C; Rubio R; Pulido F
Eur J Clin Microbiol Infect Dis; 2019 Apr; 38(4):725-734. PubMed ID: 30687869
[TBL] [Abstract][Full Text] [Related]
79. The short-term incidence of hepatocellular carcinoma is not increased after hepatitis C treatment with direct-acting antivirals: An ERCHIVES study.
Li DK; Ren Y; Fierer DS; Rutledge S; Shaikh OS; Lo Re V; Simon T; Abou-Samra AB; Chung RT; Butt AA
Hepatology; 2018 Jun; 67(6):2244-2253. PubMed ID: 29205416
[TBL] [Abstract][Full Text] [Related]
80. Hepatocellular carcinoma occurs frequently and early after treatment in HCV genotype 3 infected persons treated with DAA regimens.
Tayyab GUN; Rasool S; Nasir B; Rubi G; Abou-Samra AB; Butt AA
BMC Gastroenterol; 2020 Apr; 20(1):93. PubMed ID: 32252635
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
